Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab

British Journal of Clinical Pharmacology

Volumn 82, Issue 6, 2016, Pages 1568-1579

  Williams, Jason H ^a   Hutmacher, Matthew M ^b   Zierhut, Matthew L ^a   Becker, Jean Claude ^a   Gumbiner, Barry ^a   Spencer Green, George ^a   Melia, Lisa A ^a   Liao, Kai Hsin ^a   Suster, Matthew ^a   Yin, Donghua ^a   Li, Ruifeng ^a   Meng, Xu ^a  

^a PFIZER INC   (United States)

^b ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

Biosimilar; pharmacodynamics; pharmacokinetics

Indexed keywords

BIOSIMILAR AGENT; METHOTREXATE; METHYLPREDNISOLONE; PF 05280586; RITUXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; BIOLOGICAL MODEL; DOSE RESPONSE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RITUXIMAB; TREATMENT OUTCOME;

EID: 84988651192     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13094     Document Type: Article

References (33)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068.
2. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 2015; 172: 5729–5743.
3. Pope J, Combe B. Unmet needs in the treatment of rheumatoid arthritis. Sci Res 2013; Available at http://dx.doi.org/10.4236/ojra.2013.32011 (last accessed 6 June 2016).
4. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012; 91: 405–417.
5. US Food and Drug Administration. Title VII: improving access to innovative medical therapies. Biologic price competition and innovation (BPCIA) provisions of the Patient Protection and Affordable Care Act (PPACA). Silver Springs, MD: US Department of Health and Human Services, 2010. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf (last accessed 6 June 2016).
6. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency, 2013. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf (last accessed 6 June 2016).
7. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: World Health Organization, 2009. Available at http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (last accessed 6 June 2016).
8. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Silver Springs, MD: US Department of Health and Human Services, 2015. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf (last accessed 6 June 2016).
9. US Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: guidance for industry. Silver Springs, MD: U.S. Department of Health and Human Services, 2014. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf (last accessed 6 June 2016).
10. F. Hoffmann-La Roche Ltd. MabThera (rituximab) summary of product characteristics. Basel, Switzerland: European Medicines Agency, 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf (last accessed 6 June 2016).
11. Genentech Inc. Rituxan® (rituximab) prescribing information. South San Francisco, CA, 1997. Available at http://www.gene.com/download/pdf/rituxan_prescribing.pdf (last accessed 6 June 2016).
12. Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol 2016 82: 129–138
13. Karnik S, Thompson M, DeGruttola H, Ferrari S, Gu L, Aggarwal P, et al. Characterization and comparison of PF-05280586 – a proposed rituximab biosimilar to the licensed product. Proceedings of the American Association of Pharmaceutical Scientists-2013 National Biotechnology Conference; 20–22 May 2013; San Diego, CA.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580–1588 [correction of 2010;69:1892].
15. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502.
16. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793–2806.
17. Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12: 2546–2567.
18. Sibilia J, Gottenberg JE, Mariette X. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008; 75: 526–532.
19. Levi M, Grange S, Frey N. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 2012; 53: 151–159.
20. Hu C, Xu Z, Rahman MU, Davis HM, Zhou H. A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn 2010; 37: 309–321.
21. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 2008; 35: 139–157.
22. Lacroix BD, Karlsson MO, Friberg LE. Simultaneous exposure-response modeling of ACR20, ACR50, and ACR70 improvement scores in rheumatoid arthritis patients treated with certolizumab pegol. CPT Pharmacometrics Syst Pharmacol 2014; 3: e143.
23. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 2009; 86: 387–395.
24. Sekhon J. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011; 42: 1–52.
25. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792–801.
26. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–2581.
27. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69: 1629–1635.
28. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390–1400.
29. Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose–response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 2011; 90: 828–835.
30. Gastonguay M. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. Population Approach Group in Europe (PAGE), 2011. Available at http://www.page-meeting.org/?abstract=2229 (last accessed 6 June 2016).
31. Harrell FE. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis, 2nd edn. New York: Springer International Publishing, 2010.
32. Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gulfe A, Saxne T, et al. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken) 2014; 66: 173–179.
33. Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, et al. The combination of exposure-response and case–control analyses in regulatory decision making. J Clin Pharmacol 2013; 53: 160–166.